Thomas R. Insel

That combination.

Tom Insel, who used to be the head of the National Institute of Mental Health for well over a decade and was our major ally from the early 2000s to the, uh, around 2014 and '15, um, he said in a article that he wrote between the two months between FDA advisory committee rejecting MDMA and then the FDA rejecting MDMA, he put out this article and he said that the real innovation of MAPS was not trying to go through the FDA, but it was trying to go through the FDA with drug plus therapy.

Right.

And that that's the way that you get the best patient outcomes.